Solid Biosciences reports Q4 EPS (53c), consensus (52c)

Solid had $187.9M in cash, cash equivalents, and available-for-sale securities as of December 31, 2025, compared to $148.9M as of December 31, 2024. Bo Cumbo, president and CEO of Solid Biosciences (SLDB), commented, “We continue to build momentum across our portfolio, highlighted by updated interim INSPIRE DUCHENNE data presented at MDA, positive feedback from our FDA Type C meeting on the Phase 3 IMPACT DUCHENNE trial design for SGT-003, the dosing of our first participant in the FALCON trial for SGT-212 and the completion of an oversubscribed $240 million private placement. Together, these achievements strengthen our operational and financial foundation and position Solid to deliver on the promise of our science and improve the daily lives of people living with devastating rare diseases.”